PRODUCTS
Diagnostic Testing Solutions for Hematologic Malignancies
PRODUCTS
Diagnostic Testing Solutions for Hematologic Malignancies
Precision Oncology Diagnostics
Invivoscribe provides globally standardized hemato-oncology assay kits and workflow solutions for hematologic malignancy diagnostic testing in clinical laboratories and researchers in the areas of leukemia, lymphoma, and myeloma.
Our cGMP portfolio includes IVDR and RUO molecular diagnostics products. We offer kits for sample preparation, companion diagnostics, clonality testing, and MRD testing solutions, reagents, controls, and bioinformatics software tools designed to support precision oncology programs from assay implementation through reporting.
Precision Oncology Diagnostics
Invivoscribe provides globally standardized hemato-oncology assay kits and workflow solutions for hematologic malignancy diagnostic testing in clinical laboratories and researchers in the areas of leukemia, lymphoma, and myeloma.
Our cGMP portfolio includes IVDR and RUO molecular diagnostics products. We offer kits for sample preparation, companion diagnostics, clonality testing and MRD testing solutions, reagents, controls, and bioinformatics software tools designed to support precision oncology programs from assay implementation through reporting.
Next-Generation Sequencing
Next-Generation Sequencing
Next-generation sequencing (NGS) is revolutionizing precision medicine, enabling objective identification and tracking of genetic alterations in longitudinal studies. NGS testing for hematologic malignancies strengthens diagnosis, prognosis, risk stratification, and disease monitoring. When used for ultra-sensitive measurable residual disease (MRD) assessment, NGS can align treatment strategies with molecular drivers of disease and inform critical therapy decisions, such as bone marrow transplant operations.
Next-generation sequencing (NGS) is revolutionizing precision medicine, enabling objective identification and tracking of genetic alterations in longitudinal studies. NGS testing for hematologic malignancies strengthens diagnosis, prognosis, risk stratification, and disease monitoring. When used for ultra-sensitive measurable residual disease (MRD) assessment, NGS can align treatment strategies with molecular drivers of disease and inform critical therapy decisions, such as bone marrow transplant operations.
Lymphoid
Myeloid
ABI Fluorescence Detection
ABI Fluorescence Detection
We offer a comprehensive portfolio of PCR-based kits for hematologic malignancy diagnostic testing, including B- and T-cell clonality, mutation, and translocation assays that support accurate assessment of lymphoproliferative and myeloproliferative neoplasm disorders.
Many of our assays feature advanced primer designs developed by the EuroClonality/BIOMED-2 group and validated through large multicenter studies, delivering proven reliability, reproducibility, and high-confidence detection across gene rearrangements and mutations.
We offer a comprehensive portfolio of PCR-based kits for hematologic malignancy diagnostic testing, including B- and T-cell clonality, mutation, and translocation assays that support accurate assessment of lymphoproliferative and myeloproliferative neoplasm disorders.
Many of our assays feature advanced primer designs developed by the EuroClonality/BIOMED-2 group and validated through large multicenter studies, delivering proven reliability, reproducibility, and high-confidence detection across gene rearrangements and mutations.
Clonality
FLT3
Translocations
Gel Detection
Gel Detection
We exclusively offer a comprehensive selection of PCR-based RUO leukemia, myeloma and lymphoma assay kits for gel detection, including targeted FLT3 ITD and TKD mutation assays, B- and T-cell clonality assays (based on EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936), and translocation assays.
We exclusively offer a comprehensive selection of PCR-based RUO leukemia, myeloma and lymphoma assay kits for gel detection, including targeted FLT3 ITD and TKD mutation assays, B- and T-cell clonality assays (based on EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936), and translocation assays.
Controls & Reagents
Controls & Reagents
lnvivoscribe offers an extensive range of Assay Specific Reagents (ASRs), General Purpose Reagents (GPRs), enzymes and Research Use Only (RUO) nucleic acid controls – the assays and reagents foundation for reliable hematologic malignancy diagnostic testing workflows.
lnvivoscribe offers an extensive range of Assay Specific Reagents (ASRs), General Purpose Reagents (GPRs), enzymes and Research Use Only (RUO) nucleic acid controls – the assays and reagents foundation for reliable hematologic malignancy diagnostic testing workflows.
Controls
Reagents
Companion Diagnostics (CDx)
Companion Diagnostics (CDx)
The LeukoStrat® CDx FLT3 Mutation Assay is a globally standardized in vitro diagnostic (IVDR) PCR-based product designed to identify AML patients with mutations in the FLT3 gene who may benefit from targeted treatment.